Generation of HIV-1 Resistant and Functional Macrophages From Hematopoietic Stem Cell–derived Induced Pluripotent Stem Cells

Stem Cell Program, Department of Internal Medicine, University of California, Davis, Sacramento, California 95817, USA.
Molecular Therapy (Impact Factor: 6.23). 11/2010; 19(3):584-93. DOI: 10.1038/mt.2010.269
Source: PubMed


Induced pluripotent stem cells (iPSCs) have radically advanced the field of regenerative medicine by making possible the production of patient-specific pluripotent stem cells from adult individuals. By developing iPSCs to treat HIV, there is the potential for generating a continuous supply of therapeutic cells for transplantation into HIV-infected patients. In this study, we have used human hematopoietic stem cells (HSCs) to generate anti-HIV gene expressing iPSCs for HIV gene therapy. HSCs were dedifferentiated into continuously growing iPSC lines with four reprogramming factors and a combination anti-HIV lentiviral vector containing a CCR5 short hairpin RNA (shRNA) and a human/rhesus chimeric TRIM5α gene. Upon directed differentiation of the anti-HIV iPSCs toward the hematopoietic lineage, a robust quantity of colony-forming CD133(+) HSCs were obtained. These cells were further differentiated into functional end-stage macrophages which displayed a normal phenotypic profile. Upon viral challenge, the anti-HIV iPSC-derived macrophages exhibited strong protection from HIV-1 infection. Here, we demonstrate the ability of iPSCs to develop into HIV-1 resistant immune cells and highlight the potential use of iPSCs for HIV gene and cellular therapies.

Download full-text


Available from: Jan A Nolta, Mar 24, 2015
  • Source
    • "HSCs were derived from fresh human umbilical cord blood as described in the Supporting Information) and seeded in one well of a six-well tissue-culture-treated plate and cultured in 4 ml CD34 1 culture medium (Kambal et al., 2011): "
    [Show abstract] [Hide abstract]
    ABSTRACT: Robust strategies for developing patient-specific, human, induced pluripotent stem cell (iPSC)-based therapies of the brain require an ability to derive large numbers of highly defined neural cells. Recent progress in iPSC culture techniques includes partial-to-complete elimination of feeder layers, use of defined media, and single-cell passaging. However, these techniques still require embryoid body formation or coculture for differentiation into neural stem cells (NSCs). In addition, none of the published methodologies has employed all of the advances in a single culture system. Here we describe a reliable method for long-term, single-cell passaging of PSCs using a feeder-free, defined culture system that produces confluent, adherent PSCs that can be differentiated into NSCs. To provide a basis for robust quality control, we have devised a system of cellular nomenclature that describes an accurate genotype and phenotype of the cells at specific stages in the process. We demonstrate that this protocol allows for the efficient, large-scale, cGMP-compliant production of transplantable NSCs from all lines tested. We also show that NSCs generated from iPSCs produced with the process described are capable of forming both glia defined by their expression of S100β and neurons that fire repetitive action potentials. © 2013 Wiley Periodicals, Inc.
    Journal of Neuroscience Research 10/2013; 91(10). DOI:10.1002/jnr.23245 · 2.59 Impact Factor
  • Source
    • "Several groups have published methods for producing monocytes/and macrophages from PSC [3], [4], [5], [6], [7]. However, these methods are technically complicated, because they involve coculture on mouse stromal cells (e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human macrophages are specialised hosts for HIV-1, dengue virus, Leishmania and Mycobacterium tuberculosis. Yet macrophage research is hampered by lack of appropriate cell models for modelling infection by these human pathogens, because available myeloid cell lines are, by definition, not terminally differentiated like tissue macrophages. We describe here a method for deriving monocytes and macrophages from human Pluripotent Stem Cells which improves on previously published protocols in that it uses entirely defined, feeder- and serum-free culture conditions and produces very consistent, pure, high yields across both human Embryonic Stem Cell (hESC) and multiple human induced Pluripotent Stem Cell (hiPSC) lines over time periods of up to one year. Cumulatively, up to ∼3×10(7) monocytes can be harvested per 6-well plate. The monocytes produced are most closely similar to the major blood monocyte (CD14(+), CD16(low), CD163(+)). Differentiation with M-CSF produces macrophages that are highly phagocytic, HIV-1-infectable, and upon activation produce a pro-inflammatory cytokine profile similar to blood monocyte-derived macrophages. Macrophages are notoriously hard to genetically manipulate, as they recognise foreign nucleic acids; the lentivector system described here overcomes this, as pluripotent stem cells can be relatively simply genetically manipulated for efficient transgene expression in the differentiated cells, surmounting issues of transgene silencing. Overall, the method we describe here is an efficient, effective, scalable system for the reproducible production and genetic modification of human macrophages, facilitating the interrogation of human macrophage biology.
    PLoS ONE 08/2013; 8(8):e71098. DOI:10.1371/journal.pone.0071098 · 3.23 Impact Factor
  • Source
    • "some of them inter-dependent: (i) virus entrapment into TRIM5 cytoplasmic bodies 47 (Campbell et al., 2008), (ii) decreased stability of the virus core (Black and Aiken, 2010; 48 Perron et al., 2007; Stremlau et al., 2006; Zhao et al., 2011) (iii) targeting to a 49 proteasome-dependent degradation pathway (Anderson et al., 2006; Diaz-Griffero et al., 50 2006; Lienlaf et al., 2011; Rold and Aiken, 2008); , and (iv) inhibition of nuclear import 51 (Anderson et al., 2006; Berthoux et al., 2004; Wu et al., 2006). The linear structure of 52 TRIM5 reveals a partition between effector domains at the N-terminus and a target 53 recognition domain called PRYSPRY (also known as SPRY or B30.2) found at the C- 54 terminus. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human-derived antiretroviral transgenes are of great biomedical interest and are actively pursued. HIV-1 is efficiently inhibited at post-entry, pre-integration replication stages by point mutations in the variable region 1 (v1) of the human restriction factor TRIM5α. Here we use a mutated megaprimer approach to create a mutant library of TRIM5αHu v1 and to isolate a mutation at Gly330 (G330E) that inhibits transduction of an HIV-1 vector as efficiently as the previously described mutants at positions Arg332 and Arg335. As was the case for these other mutations, modification of the local v1 charge toward increased acidity was key to inhibiting HIV-1. G330E TRIM5αHu also disrupted replication-competent HIV-1 propagation in a human T cell line. Interestingly, G330E did not enhance restriction of HIV-1 when combined with mutations at Arg332 or Arg335. Accordingly, the triple mutant G330E-R332G-R335G bound purified recombinant HIV-1 capsid tubes less efficiently than the double mutant R332G-R335G did. In a structural model of the TRIM5αHu PRYSPRY domain, the addition of G330E to the double mutant R332G-R335G caused extensive changes to the capsid-binding surface, which may explain why the triple mutant was no more restrictive than the double mutant. The HIV-1 inhibitory potential of Gly330 mutants was not predicted by examination of natural TRIM5α orthologs that are known to strongly inhibit HIV-1. This work underlines the potential of random mutagenesis to isolate novel variants of human proteins with antiviral properties.
    Virus Research 01/2013; 173(2). DOI:10.1016/j.virusres.2013.01.013 · 2.32 Impact Factor
Show more